These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. 'Designer drugs'. A problem in clinical toxicology. Buchanan JF; Brown CR Med Toxicol Adverse Drug Exp; 1988; 3(1):1-17. PubMed ID: 3285124 [TBL] [Abstract][Full Text] [Related]
5. An autopsy case of acetyl fentanyl intoxication caused by insufflation of 'designer drugs'. Takase I; Koizumi T; Fujimoto I; Yanai A; Fujimiya T Leg Med (Tokyo); 2016 Jul; 21():38-44. PubMed ID: 27497332 [TBL] [Abstract][Full Text] [Related]
7. [Not all drugs are the same]. Weilemann LS Med Klin Intensivmed Notfmed; 2013 Sep; 108(6):484-90. PubMed ID: 23974649 [TBL] [Abstract][Full Text] [Related]
8. "Designer drugs"--a current perspective. Jerrard DA J Emerg Med; 1990; 8(6):733-41. PubMed ID: 2096172 [TBL] [Abstract][Full Text] [Related]
9. Epidemiological study of acute poisoning in children: a 5-year retrospective study in the Paediatric University Hospital in Białystok, Poland. Pawłowicz U; Wasilewska A; Olański W; Stefanowicz M Emerg Med J; 2013 Sep; 30(9):712-6. PubMed ID: 22942363 [TBL] [Abstract][Full Text] [Related]
10. MDA, MDMA, and other "mescaline-like" substances in the US military's search for a truth drug (1940s to 1960s). Passie T; Benzenhöfer U Drug Test Anal; 2018 Jan; 10(1):72-80. PubMed ID: 28851034 [TBL] [Abstract][Full Text] [Related]
11. Designer drugs: a medicinal chemistry perspective. Carroll FI; Lewin AH; Mascarella SW; Seltzman HH; Reddy PA Ann N Y Acad Sci; 2012 Feb; 1248():18-38. PubMed ID: 22092008 [TBL] [Abstract][Full Text] [Related]
13. [Metabolism of designer drugs. The fentanyl derivatives]. Melent'ev AB; Kataev SS Sud Med Ekspert; 2015; 58(5):39-46. PubMed ID: 26710514 [TBL] [Abstract][Full Text] [Related]
14. "Not for human consumption": a review of emerging designer drugs. Musselman ME; Hampton JP Pharmacotherapy; 2014 Jul; 34(7):745-57. PubMed ID: 24710806 [TBL] [Abstract][Full Text] [Related]
15. Opioids and designer drugs. Ford M; Hoffman RS; Goldfrank LR Emerg Med Clin North Am; 1990 Aug; 8(3):495-511. PubMed ID: 2201517 [TBL] [Abstract][Full Text] [Related]
16. The evolving high: new designer drugs of abuse. Pourmand A; Armstrong P; Mazer-Amirshahi M; Shokoohi H Hum Exp Toxicol; 2014 Oct; 33(10):993-9. PubMed ID: 24501103 [TBL] [Abstract][Full Text] [Related]
17. [Toxicologic analysis in emergencies]. Feuillu A Ann Biol Clin (Paris); 2000; 58(6):753-4. PubMed ID: 11098177 [No Abstract] [Full Text] [Related]
18. Rapid detection, toxicosurveillance and public health response to stimulant adulteration with acetyl fentanyl. Perananthan V; Tremonti C; Nash E; Jiranantakan T; Dawson AH Med J Aust; 2021 Jun; 214(11):533-533.e1. PubMed ID: 34050540 [No Abstract] [Full Text] [Related]
19. Designer drugs: Review and implications for emergency management. Pourmand A; Mazer-Amirshahi M; Chistov S; Li A; Park M Hum Exp Toxicol; 2018 Jan; 37(1):94-101. PubMed ID: 28764574 [TBL] [Abstract][Full Text] [Related]
20. Combatting Synthetic Designer Opioids: A Conjugate Vaccine Ablates Lethal Doses of Fentanyl Class Drugs. Bremer PT; Kimishima A; Schlosburg JE; Zhou B; Collins KC; Janda KD Angew Chem Int Ed Engl; 2016 Mar; 55(11):3772-5. PubMed ID: 26879590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]